LVTX
LAVA Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LVTX
Lava Therapeutics N.V.
A clinical-stage immuno-oncology company that develops new cancer treatments that leverage the immune system
Biological Technology
02/15/2016
03/25/2021
NASDAQ Stock Exchange
34
12-31
Common stock
Yalelaan 62, 3584 CM Utrecht, The Netherlands
--
LAVA Therapeutics N.V. was incorporated in the Netherlands on February 15, 2016. The company is a clinical-stage immuno-oncology company dedicated to the rapid development of new cancer treatments that harness the immune system to save patients' lives. Utilizing the company's Gammabody platform, the company is developing a series of novel bispecific antibodies designed to harness the potency and precision of γ-δ (gd) T cells to elicit a powerful natural anti-tumor immune response and improve the prognosis of cancer patients.
Company Financials
EPS
LVTX has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected -0.414622, beating expectations. The chart below visualizes how LVTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
